Allspring Global Investments Holdings LLC Has $157,000 Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Allspring Global Investments Holdings LLC raised its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 14.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,863 shares of the company’s stock after purchasing an additional 1,582 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Intellia Therapeutics were worth $157,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. State Street Corp raised its holdings in Intellia Therapeutics by 17.9% in the 3rd quarter. State Street Corp now owns 5,143,534 shares of the company’s stock valued at $105,700,000 after buying an additional 780,754 shares during the last quarter. ARK Investment Management LLC increased its position in Intellia Therapeutics by 5.7% in the 3rd quarter. ARK Investment Management LLC now owns 12,255,440 shares of the company’s stock valued at $251,849,000 after acquiring an additional 659,651 shares during the period. Two Sigma Advisers LP raised its stake in shares of Intellia Therapeutics by 33.5% during the third quarter. Two Sigma Advisers LP now owns 1,027,617 shares of the company’s stock valued at $21,118,000 after acquiring an additional 257,700 shares during the last quarter. Sphera Funds Management LTD. lifted its holdings in shares of Intellia Therapeutics by 108.8% during the third quarter. Sphera Funds Management LTD. now owns 291,080 shares of the company’s stock worth $5,982,000 after purchasing an additional 151,661 shares during the period. Finally, Patient Square Capital LP acquired a new position in shares of Intellia Therapeutics during the third quarter worth $2,642,000. 88.77% of the stock is owned by institutional investors and hedge funds.

Intellia Therapeutics Stock Performance

NTLA stock opened at $10.71 on Wednesday. The stock’s 50 day simple moving average is $10.99 and its 200 day simple moving average is $15.87. The company has a market cap of $1.09 billion, a P/E ratio of -1.97 and a beta of 1.80. Intellia Therapeutics, Inc. has a fifty-two week low of $8.96 and a fifty-two week high of $34.87.

Insider Buying and Selling

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of the company’s stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total transaction of $326,509.26. Following the transaction, the chief executive officer now owns 941,115 shares in the company, valued at approximately $11,462,780.70. This represents a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders have sold a total of 29,000 shares of company stock worth $352,551 in the last ninety days. Corporate insiders own 3.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on NTLA. BMO Capital Markets lowered their target price on Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating for the company in a research report on Friday, January 10th. Canaccord Genuity Group restated a “buy” rating and set a $90.00 price objective on shares of Intellia Therapeutics in a research report on Tuesday, November 19th. The Goldman Sachs Group cut their price objective on Intellia Therapeutics from $19.00 to $12.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 14th. Chardan Capital increased their target price on shares of Intellia Therapeutics from $88.00 to $91.00 and gave the company a “buy” rating in a research report on Monday, November 18th. Finally, Barclays lowered their price target on shares of Intellia Therapeutics from $76.00 to $55.00 and set an “overweight” rating for the company in a report on Friday, November 8th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $48.71.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.